HSBC Global Research has issued a research report stating that it maintains its "Hold" rating on Giant Biogene (2367.HK), but has cut its target price by 26% from HK$28.1 to HK$20.7, citing lower earnings forecasts and a reduction in its target price-to-earnings ratio from 13.1x to 9.8x.
HSBC pointed out that despite a low base in the second half of last year, the group's core brand KOMFYMED recorded only 5% year-on-year GMV growth during this year's "Double 11" shopping festival, a disappointing performance that fell far short of market expectations for a recovery.
Breaking down brand performance and growth bottlenecks, HSBC said that although the smaller brand Collgene recorded 25% growth during the "Double 11" period, the flagship brand KOMFYMED still delivered lackluster results during the major promotion despite a low base of a 22% year-on-year decline in the second half of 2025, further confirming the bank's earlier cautious view on its recovery prospects.
The bank believes that KOMFYMED's long-term growth potential is increasingly in question. The brand, once widely expected by the market to reach annual sales of RMB 8 billion, now appears to have stalled below RMB 5 billion, with the main problem being over-reliance on a single blockbuster product (recombinant collagen essence), while product upgrades and iterations have had limited effect in driving overall growth.
Based on weaker growth assumptions for KOMFYMED, HSBC has lowered its revenue forecasts for Giant Biogene for fiscal years 2026 to 2028 by 5%, 8%, and 11%, respectively, and correspondingly cut its net profit forecasts for the same periods by 3.3%, 2%, and 2.6%. After adjustments, the bank's revenue forecasts for Giant Biogene in 2026 and 2027 are 5.5% and 10.0% below consensus estimates, while net profit forecasts are 3.9% and 9.2% below market expectations, respectively.
Comments